US2011094885A1PendingUtilityA1
Flexible Drug Delivery Chip, its Fabrication Method and Uses Thereof
Est. expirySep 7, 2029(~3.1 yrs left)· nominal 20-yr term from priority
A61K 9/0024A61M 37/00C25D 13/04A61K 31/4015A61P 25/08C25D 13/14A61K 9/0009
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring the concentration and distribution of the released drugs and/or active compounds injected separately into a target site of a subject.
Claims
exact text as granted — not AI-modified1 . A method of fabricating a drug-containing cell, comprising:
providing a flexible substrate; constructing a drug-containing reservoir by forming a plurality of side walls on the flexible substrate to define a drug-containing volume thereon, wherein at least one side of the drug-containing volume is not sealed by the plurality of side walls; electrophoretically depositing a first layer of drug-containing nanoparticles on the flexible substrate in the drug-containing volume, forming a layer of metal on the first layer of drug-containing nanoparticles by sputter deposition; and electrophoretically depositing a second layer of drug-containing nanoparticles on the metal layer.
2 . The method of claim 1 , wherein the electrophoretic deposition is performed by steps of:
providing an electrophoretic deposition cell, which comprises:
a colloidal suspension containing about 0.01-30% by weight of drug-containing nanoparticles; and
a pair of electrodes;
immersing the flexible substrate having constructed thereon the drug-containing reservoir in the colloidal suspension in the electrophoretic deposition cell; and applying a voltage of about 1-50 V to the pair of electrodes for a period of about 1-30 min or until the layer of drug-containing nanoparticles has a thickness of at least 0.1 μm.
3 . The method of claim 2 , wherein the colloidal suspension is prepared by suspending the drug-containing nanoparticles in a diluting medium selected from the group consisting of water, a C 1-6 alcohol, glycol, glycerin, dimethyl sulfoxide and a combination thereof.
4 . The method of claim 1 , wherein a gap of about 0.5 cm to about 5 cm is formed between the pair of electrodes.
5 . The method of claim 1 , wherein the electrophoretic deposition is carried out at a temperature ranges from about −10° C. to about 70° C.
6 . The method of claim 1 , wherein the metal is selected form the group consisting of Au, Ag, Pt, and Ta.
7 . The method of claim 1 , wherein the plurality of side walls are made of a biocompatible material that is selected from the group consisting of collagen, polyvinylchloride (PVC), polylactide, polyethylene glycol, polycaprolactone (PCL), polycolide, polydioxanone, and derivatives and copolymers thereof.
8 . The method of claim 1 , wherein the flexible substrate is made of a material selected from the group consisting of polyethylene terephthalate (PET), polyethylene, ethylene-vinyl acetate, polyimides, polyamides, polyethylene naphthalate (PEN), polyimide (PI) and polyaryletheretherketone (PEEK).
9 . The method of claim 1 , wherein each of the drug-containing nanoparticles comprises a magnetic iron oxide-containing core and a silicon dioxide shell, and a drug is encapsulated within the magnetic iron oxide-containing core.
10 . The method of claim 9 , wherein the drug is ethosuximide.Join the waitlist — get patent alerts
Track US2011094885A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.